IP GROUP
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN
Tissue Regenix Group plc
("Tissue Regenix" or the "Company")
Result of General Meeting
Tissue Regenix (AIM:TRX) is pleased to announce that at the General Meeting held today, all the proposed resolutions in connection with the Placing announced by the Company on 22 January 2015, were duly passed.
Accordingly, the Company has applied to the London Stock Exchange for 105,263,158 new Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will occur at 8.00 a.m. on 10 February 2015.
Following admission of the 105,263,158 new Ordinary Shares to trading on AIM, the total number of Ordinary Shares with voting rights in issue will be 759,412,853 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
Upon admission, the new Ordinary Shares will be issued, credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares of the Company.
Enquiries:
Tissue Regenix Group plc
Antony Odell, Chief Executive Officer
Ian Jefferson, Chief Financial Officer
Tel: 019 0443 5176
Jefferies International Limited (Nomad, broker and bookrunner)
Simon Hardy
Harry Nicholas
Tel: 020 7029 8000
Tulchan Communications
Tom Buchanan / Victoria Huxster
Tel: 020 7353 4200
|
distributed by
|
